JP2012502105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502105A5 JP2012502105A5 JP2011526972A JP2011526972A JP2012502105A5 JP 2012502105 A5 JP2012502105 A5 JP 2012502105A5 JP 2011526972 A JP2011526972 A JP 2011526972A JP 2011526972 A JP2011526972 A JP 2011526972A JP 2012502105 A5 JP2012502105 A5 JP 2012502105A5
- Authority
- JP
- Japan
- Prior art keywords
- iloperidone
- patient
- cyp2d6
- disorder
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 18
- 229960003162 iloperidone Drugs 0.000 claims 18
- 238000000034 method Methods 0.000 claims 8
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 7
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 7
- 208000020016 psychiatric disease Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 108700028369 Alleles Proteins 0.000 claims 4
- -1 P88 Chemical compound 0.000 claims 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/208,027 US20100063093A1 (en) | 2007-03-28 | 2008-09-10 | Methods for the administration of iloperidone |
| US12/208,027 | 2008-09-10 | ||
| PCT/US2009/056517 WO2010030783A1 (en) | 2008-09-10 | 2009-09-10 | Methods for the administration of iloperidone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502105A JP2012502105A (ja) | 2012-01-26 |
| JP2012502105A5 true JP2012502105A5 (enExample) | 2012-11-01 |
Family
ID=41280442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011526972A Pending JP2012502105A (ja) | 2008-09-10 | 2009-09-10 | イロペリドンの投与方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20100063093A1 (enExample) |
| EP (2) | EP3492081A1 (enExample) |
| JP (1) | JP2012502105A (enExample) |
| AU (1) | AU2009291717A1 (enExample) |
| CA (1) | CA2736245C (enExample) |
| ES (1) | ES2688476T3 (enExample) |
| SI (1) | SI2331098T1 (enExample) |
| WO (1) | WO2010030783A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| CA3113166A1 (en) * | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| CN108938632A (zh) * | 2012-03-14 | 2018-12-07 | 万达制药公司 | 用于治疗精神疾病的伊潘立酮代谢物及其应用 |
| JP6885649B2 (ja) * | 2015-02-17 | 2021-06-16 | バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 統合失調症の治療のためのイロペリドン |
| US11214827B2 (en) | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US5130238A (en) * | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| GB9001181D0 (en) * | 1990-01-18 | 1990-03-21 | Imp Cancer Res Tech | Genetic assay |
| US5846717A (en) * | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| EP1242058A1 (en) | 1999-04-07 | 2002-09-25 | Pfizer Products Inc. | Use of cyp2d6 inhibitors in combination therapies |
| US20010034023A1 (en) * | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
| US6960439B2 (en) * | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US7179597B2 (en) * | 2000-04-13 | 2007-02-20 | Georgetown University | Genetic diagnosis for QT prolongation related adverse drug reactions |
| US6761895B2 (en) * | 2000-04-17 | 2004-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
| WO2001096604A2 (en) * | 2000-06-12 | 2001-12-20 | Genicon Sciences Corporation | Assay for genetic polymorphisms using scattered light detectable labels |
| GB0102841D0 (en) | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| WO2002073196A2 (en) * | 2001-03-14 | 2002-09-19 | Mcgill University | Individualization of therapy with antipsychotics |
| US7195877B2 (en) * | 2001-07-20 | 2007-03-27 | Bioventures, Inc. | Cytochrome P450 genetic variations |
| EP1281755A3 (en) * | 2001-07-31 | 2003-06-18 | Pfizer Products Inc. | Variants of the human cyp2d6 gene |
| ES2370634T3 (es) * | 2001-08-31 | 2011-12-21 | Novartis Ag | Isómeros ópticos de un metabolito de iloperidona. |
| WO2003037337A1 (en) * | 2001-10-30 | 2003-05-08 | Novartis Ag | Depot formulations of iloperidone and a star polymer |
| JP2005507261A (ja) | 2001-10-31 | 2005-03-17 | ノバルティス アクチエンゲゼルシャフト | Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法 |
| AU2002358110A1 (en) | 2001-12-10 | 2003-07-09 | Novartis Ag | Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene |
| US20040096874A1 (en) * | 2002-04-11 | 2004-05-20 | Third Wave Technologies, Inc. | Characterization of CYP 2D6 genotypes |
| US20040091909A1 (en) * | 2002-07-05 | 2004-05-13 | Huang Doug Hui | High throughput cytochrome P450 genotyping |
| US20050032070A1 (en) * | 2003-08-05 | 2005-02-10 | Sebastian Raimundo | Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications |
| US20080166357A1 (en) * | 2004-05-11 | 2008-07-10 | Stefan Golz | Diagnostics and Therapeutics for Diseases Associated with Dipeptidyl-Peptidase 6 (Dpp6) |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| CA3113166A1 (en) * | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| JP5586094B2 (ja) * | 2007-03-29 | 2014-09-10 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Ｑｔ延長に対する素因を予測する方法 |
| EP3075865B1 (en) * | 2007-05-18 | 2018-05-09 | Vanda Pharmaceuticals Inc. | Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms |
-
2008
- 2008-09-10 US US12/208,027 patent/US20100063093A1/en not_active Abandoned
-
2009
- 2009-09-10 JP JP2011526972A patent/JP2012502105A/ja active Pending
- 2009-09-10 AU AU2009291717A patent/AU2009291717A1/en not_active Abandoned
- 2009-09-10 EP EP18187366.2A patent/EP3492081A1/en not_active Withdrawn
- 2009-09-10 ES ES09792421.1T patent/ES2688476T3/es active Active
- 2009-09-10 CA CA2736245A patent/CA2736245C/en active Active
- 2009-09-10 EP EP09792421.1A patent/EP2331098B1/en active Active
- 2009-09-10 SI SI200931877T patent/SI2331098T1/sl unknown
- 2009-09-10 WO PCT/US2009/056517 patent/WO2010030783A1/en not_active Ceased
-
2013
- 2013-10-02 US US14/044,183 patent/US20140039008A1/en not_active Abandoned
-
2015
- 2015-09-08 US US14/847,784 patent/US20160053324A1/en not_active Abandoned
-
2019
- 2019-05-08 US US16/406,229 patent/US20190360047A1/en not_active Abandoned
-
2022
- 2022-04-08 US US17/716,968 patent/US20220259660A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020033360A5 (enExample) | ||
| JP2014517050A5 (enExample) | ||
| NZ604029A (en) | Methods of treating bladder cancer | |
| JP2014528474A5 (enExample) | ||
| JP2015524444A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| JP2009525343A5 (enExample) | ||
| JP2002532392A5 (enExample) | ||
| JP2012520866A5 (enExample) | ||
| JP2010526837A5 (enExample) | ||
| JP2021080276A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| JP2013541583A5 (enExample) | ||
| JP2014514271A5 (enExample) | ||
| WO2006017816A3 (en) | Product and process for inhibition of biofilm development | |
| JP2013518124A5 (enExample) | ||
| JP2018522920A5 (enExample) | ||
| JP2012502105A5 (enExample) | ||
| JP2008509224A5 (enExample) | ||
| JP2017528521A5 (enExample) | ||
| JP2024016113A (ja) | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2016505050A5 (enExample) | ||
| JP2011500589A5 (enExample) | ||
| JP2013536206A5 (enExample) | ||
| JP2019507786A5 (enExample) |